Page 53 - 林口醫研部 9月電子報

•Figure 2. PRKDC knockout increased immunotherapy response in vivo. (A)

Left panel shows CT26 with or without knockout PRKDC and γH2A.X

expression levels were performed by western blotting using CT26 parental
cell, CT26 PRKDC-knockout cell (short-term) and CT26 PRKDC- knockout cell

passaged more 10 generations (long-term). Representative photographs in

the right panel of tumor size (n=4 per treatment group). (B) no significant
change in body weight in each group. (C) Tumor weight showed consistency

with tumor volume; CT26 PRKDC-knockout mice combined with anti-PD-L1

had lower tumor weight than that of mice in the sham group. (D) Anti-PD-L1
led to a significant decrease in CT26 cell growth in vivo, compared with the

sham group (p=6.09×106). A combination of CT26 PRKDC-knockout and

anti-PD-L1 inhibited tumorigenicity, compared with the sham group

(p<0.001). (A-D) The statistical significance was analyzed using unpaired t-
test. NS, not significant; PD-L1, programmed cell death protein one pathway;

PRKDC, protein kinase, DNA-activated, catalytic polypeptide.

Department of Medical Research & Development, Linkou Newsletter 53